Literature DB >> 22068166

Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models.

Zobeida Cruz-Monserrate1, Wael R Abd-Elgaliel, Tobias Grote, Defeng Deng, Baoan Ji, Thiruvengadam Arumugam, Huamin Wang, Ching-Hsuan Tung, Craig D Logsdon.   

Abstract

BACKGROUND AND AIMS: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the USA. Surgical resection is the only effective treatment; however, only 20% of patients are candidates for surgery. The ability to detect early PDAC would increase the availability of surgery and improve patient survival. This study assessed the feasibility of using the enzymatic activity of cathepsin E (Cath E), a protease highly and specifically expressed in PDAC, as a novel biomarker for the detection of pancreas-bearing pancreatic intraepithelial neoplasia (PanIN) lesions and PDAC.
METHODS: Pancreas from normal, chronic pancreatitis and PDAC patients was assessed for Cath E expression by quantitative real-time PCR and immunohistochemistry. Human PDAC xenografts and genetically engineered mouse models (GEMM) of PDAC were injected with a Cath E activity selective fluorescent probe and imaged using an optical imaging system.
RESULTS: The specificity of Cath E expression in PDAC patients and GEMM of pancreatic cancer was confirmed by quantitative real-time PCR and immunohistochemistry. The novel probe for Cath E activity specifically detected PDAC in both human xenografts and GEMM in vivo. The Cath E sensitive probe was also able to detect pancreas with PanIN lesions in GEMM before tumour formation.
CONCLUSIONS: The elevated Cath E expression in PanIN and pancreatic tumours allowed in-vivo detection of human PDAC xenografts and imaging of pancreas with PanIN and PDAC tumours in GEMM. Our results support the usefulness of Cath E activity as a potential molecular target for PDAC and early detection imaging.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22068166      PMCID: PMC3966534          DOI: 10.1136/gutjnl-2011-300544

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  40 in total

1.  Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer.

Authors:  Kunihiko Izuishi; Yuka Yamamoto; Takanori Sano; Ryusuke Takebayashi; Tsutomu Masaki; Yasuyuki Suzuki
Journal:  J Gastrointest Surg       Date:  2010-05-05       Impact factor: 3.452

2.  Plectin-1 as a novel biomarker for pancreatic cancer.

Authors:  Dirk Bausch; Stephanie Thomas; Mari Mino-Kenudson; Castillo Carlos Fernández-del; Todd W Bauer; Mark Williams; Andrew L Warshaw; Sarah P Thayer; Kimberly A Kelly
Journal:  Clin Cancer Res       Date:  2010-11-23       Impact factor: 12.531

3.  EUS/EUS-FNA for suspected pancreatic cancer: influence of chronic pancreatitis and clinical presentation with or without obstructive jaundice on performance characteristics.

Authors:  Naveen B Krishna; Mohit Mehra; Amith V Reddy; Banke Agarwal
Journal:  Gastrointest Endosc       Date:  2009-02-27       Impact factor: 9.427

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  In vivo diagnosis of murine pancreatic intraepithelial neoplasia and early-stage pancreatic cancer by molecular imaging.

Authors:  Stefan Eser; Marlena Messer; Philipp Eser; Alexander von Werder; Barbara Seidler; Monther Bajbouj; Roger Vogelmann; Alexander Meining; Johannes von Burstin; Hana Algül; Philipp Pagel; Angelika E Schnieke; Irene Esposito; Roland M Schmid; Günter Schneider; Dieter Saur
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-31       Impact factor: 11.205

6.  Detection of precursor lesions of pancreatic adenocarcinoma in PET-CT in a genetically engineered mouse model of pancreatic cancer.

Authors:  Volker Fendrich; Ralph Schneider; Anirban Maitra; Ilse D Jacobsen; Thomas Opfermann; Detlef K Bartsch
Journal:  Neoplasia       Date:  2011-02       Impact factor: 5.715

7.  Selective detection of Cathepsin E proteolytic activity.

Authors:  Wael R Abd-Elgaliel; Ching-Hsuan Tung
Journal:  Biochim Biophys Acta       Date:  2010-06-19

8.  Markers of pancreatic cancer: working toward early detection.

Authors:  Michael Goggins
Journal:  Clin Cancer Res       Date:  2011-02-08       Impact factor: 12.531

9.  Ras activity levels control the development of pancreatic diseases.

Authors:  Baoan Ji; Lilian Tsou; Huamin Wang; Sebastian Gaiser; David Z Chang; Jaroslaw Daniluk; Yan Bi; Tobias Grote; Daniel S Longnecker; Craig D Logsdon
Journal:  Gastroenterology       Date:  2009-06-06       Impact factor: 22.682

10.  Detection of pancreatic carcinomas by imaging lactose-binding protein expression in peritumoral pancreas using [18F]fluoroethyl-deoxylactose PET/CT.

Authors:  Leo Garcia Flores; Susanna Bertolini; Hsin Hsin Yeh; Daniel Young; Uday Mukhopadhyay; Ashutosh Pal; Yunming Ying; Andrei Volgin; Aleksandr Shavrin; Suren Soghomonyan; William Tong; William Bornmann; Mian M Alauddin; Craig Logsdon; Juri G Gelovani
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more
  29 in total

Review 1.  Fluorescent imaging of cancerous tissues for targeted surgery.

Authors:  Lihong Bu; Baozhong Shen; Zhen Cheng
Journal:  Adv Drug Deliv Rev       Date:  2014-07-24       Impact factor: 15.470

Review 2.  Pathogenesis of pancreatic cancer: lessons from animal models.

Authors:  L Charles Murtaugh
Journal:  Toxicol Pathol       Date:  2013-10-31       Impact factor: 1.902

Review 3.  Challenges of Pancreatic Cancer.

Authors:  Julien Dimastromatteo; Jacob L Houghton; Jason S Lewis; Kimberly A Kelly
Journal:  Cancer J       Date:  2015 May-Jun       Impact factor: 3.360

4.  Global identification of peptidase specificity by multiplex substrate profiling.

Authors:  Anthony J O'Donoghue; A Alegra Eroy-Reveles; Giselle M Knudsen; Jessica Ingram; Min Zhou; Jacob B Statnekov; Alexander L Greninger; Daniel R Hostetter; Gang Qu; David A Maltby; Marc O Anderson; Joseph L Derisi; James H McKerrow; Alma L Burlingame; Charles S Craik
Journal:  Nat Methods       Date:  2012-09-30       Impact factor: 28.547

Review 5.  The role of stroma in pancreatic cancer: diagnostic and therapeutic implications.

Authors:  Mert Erkan; Simone Hausmann; Christoph W Michalski; Alexander A Fingerle; Martin Dobritz; Jörg Kleeff; Helmut Friess
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-06-19       Impact factor: 46.802

6.  Pancreatic cancer-associated Cathepsin E as a drug activator.

Authors:  Wael R Abd-Elgaliel; Zobeida Cruz-Monserrate; Huamin Wang; Craig D Logsdon; Ching-Hsuan Tung
Journal:  J Control Release       Date:  2013-02-26       Impact factor: 9.776

7.  Prospective markers for early diagnosis and prognosis of sporadic pancreatic ductal adenocarcinoma.

Authors:  Martin Tobi; Mijin Kim; Douglas H Weinstein; Mary Ann Rambus; James Hatfield; N Volkan Adsay; Edi Levi; Douglas Evans; Michael J Lawson; Suzanne Fligiel
Journal:  Dig Dis Sci       Date:  2012-09-22       Impact factor: 3.199

8.  Targeting cathepsin E in pancreatic cancer by a small molecule allows in vivo detection.

Authors:  Edmund J Keliher; Thomas Reiner; Sarah Earley; Jenna Klubnick; Carlos Tassa; Andrew J Lee; Sridhar Ramaswamy; Nabeel Bardeesy; Douglas Hanahan; Ronald A Depinho; Cesar M Castro; Ralph Weissleder
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

9.  Procathepsin E is highly abundant but minimally active in pancreatic ductal adenocarcinoma tumors.

Authors:  Anthony J O'Donoghue; Sam L Ivry; Chaity Chaudhury; Daniel R Hostetter; Douglas Hanahan; Charles S Craik
Journal:  Biol Chem       Date:  2016-09-01       Impact factor: 3.915

Review 10.  Cathepsin E expression and activity: Role in the detection and treatment of pancreatic cancer.

Authors:  Corbin Pontious; Sabrina Kaul; Marcus Hong; Phil A Hart; Somashekar G Krishna; Luis F Lara; Darwin L Conwell; Zobeida Cruz-Monserrate
Journal:  Pancreatology       Date:  2019-09-20       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.